Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of lutetium (177Lu) rhPSMA-10.1 in metastatic castration-resistant prostate cancer
NL-OMON56388Phase 2Recruiting
- Sponsor
- Blue Earth Therapeutics
- Start
- Feb 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium (177Lu) rhPSMA-10.1 in prostate cancer (PCa) (2 arms), sponsored by Blue Earth Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities, Treatment-emergent adverse events and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
lutetium (177Lu) rhPSMA-10.1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON56388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56388.